# Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

> **NCT04327089** · PHASE1 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 64 (actual)

## Conditions studied

- Phase 1

## Interventions

- **DRUG:** Setanaxib

## Key facts

- **NCT ID:** NCT04327089
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-24
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-03-23
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327089, "Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04327089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*